Research
Vir hepatitis D drug succeeds in first pivotal study
BioPharma Dive · By Delilah Alvarado ·
The Brief
- Vir Biotechnology's hepatitis D drug hit all study objectives in its first pivotal study.
- The program survived Vir's pivot away from infectious disease research.
- The drug appeared more potent than a rival hepatitis D drug also in late-stage development.
Why it matters
Hepatitis D is a severe form of viral hepatitis with limited treatment options, so a positive pivotal result signals a possible new therapy for patients and is a step toward regulatory review.
Who’s affected
- hepatologists and infectious disease clinicians
- patients with chronic hepatitis D
- biotech investors following Vir Biotechnology
- #hepatitis d
- #vir biotechnology
- #clinical trial
- #antiviral
- #drug development
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
Timeline
BioPharma Dive reports that Vir's hepatitis D drug succeeded in its first pivotal study
BioPharma Dive - Latest News
Vir hepatitis D drug succeeds in first pivotal study